<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728610</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-2</org_study_id>
    <nct_id>NCT01728610</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms</brief_title>
  <official_title>Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms (IBS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse the effect of a probiotic supplement on functional
      intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the intervention is to analyse the effect of a probiotic supplement in a
      dose-responsive set up on functional intestinal symptoms among subjects diagnosed with IBS
      according to Rome III criteria. Subjective assessment of bowel symptoms, quality of life,
      anxiety and depression and adequate relief will be assessed as with questionnaires as outcome
      measures. The intestinal microbiota will be analysed from faecal samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in functional bowel symptoms</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <description>Validated questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <description>Validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety and depression</measure>
    <time_frame>0 weeks, 4 weeks and 12 weeks</time_frame>
    <description>Validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate relief</measure>
    <time_frame>Weekly over 3 month intervention</time_frame>
    <description>Weekly question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal microbiota</measure>
    <time_frame>0 weeks, 4 weeks, 12 weeks</time_frame>
    <description>Detection and quantification of microbes from faecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of investigational product</measure>
    <time_frame>Throughout the intervention phase</time_frame>
    <description>Recording of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Active high</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic, high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic, low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic (Active high)</intervention_name>
    <description>Higher dose of probiotic supplement</description>
    <arm_group_label>Active high</arm_group_label>
    <other_name>Lactobacillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic (Active low)</intervention_name>
    <description>Lower dose of probiotic supplement</description>
    <arm_group_label>Active low</arm_group_label>
    <other_name>Lactobacillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maltodextrin as placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 65 fulfilling Rome III criteria for IBS will be recruited.
             Sufficient general health and orientation for participating in the study is required
             and will be evaluated by the MDs.

        Exclusion Criteria:

          -  Diagnosed or suspected organic gastrointestinal diseases or severely impaired general
             health.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lea Veijola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herttoniemi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Ouwehand, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sampo Lahtinen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lyra, PhD</last_name>
    <role>Study Director</role>
    <affiliation>DuPont Nutrition and Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mehiläinen Töölö</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Turku</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>probiotic</keyword>
  <keyword>pain</keyword>
  <keyword>bloating</keyword>
  <keyword>diarrhoea</keyword>
  <keyword>constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

